SCHEMBL4600760

SCHEMBL4600760

Fc1cccc(Nc2ncc(Br)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.49
CYP1A1 P04798 4/20 0.45
CYP1A2 P05177 4/20 0.45
CYP1B1 Q16678 4/20 0.45
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
PKM P14618 2/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EGFR P00533 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
RAPGEF4 Q8WZA2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601487 0.81 RAB9A (0.62) KDRRAB9ANPC1MAPK1HTT
SCHEMBL15689102 0.81 MEN1 (0.51) KDRCYP1A1CYP1A2CYP1B1NPC1
SCHEMBL4601020 0.81 KIF11 (0.51) KDRMEN1KMT2A
SCHEMBL4601162 0.80 KDR (0.50) KDRCYP1A1CYP1A2CYP1B1RAB9A
SCHEMBL4601132 0.80 KDR (0.62) KDRCDK2RAB9ANPC1MEN1
SCHEMBL4601587 0.78 SYK (0.47) KDRCDK2EGFRABCG2
SCHEMBL4601039 0.78 MEN1 (0.54) KDRCYP1A1CYP1A2CYP1B1PKM
SCHEMBL4601253 0.78 CFTR (0.48) KDRRAB9ANPC1SMN1; SMN2EGFR
SCHEMBL4600869 0.77 RHOA (0.51) KDRRAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL14056912 0.76 RET (0.46) KDRCYP1A2RAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101273023-A 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-09-24 CN claimed
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US claimed
EP-1912959-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-23 EP claimed
WO-2007016228-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-08 WO claimed
CN-101273023-A 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-09-24 CN disclosed
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US disclosed
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US disclosed
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US disclosed
WO-2007016228-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors BMX, CDK1, CKS1B KDR 1104/4885CYP1A1 2498/4885CYP1A2 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.